PLoS ONE · 2018 · 18 citations · 62 references
Life SciencesImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyAntibody CharacterizationAntibody StructureGlycan StructureGlycan-protein InteractionsHiv Vaccine DevelopmentViral VaccinesAntibodiesAntibody Glycan RecognitionGlycosylation SitesHiv Envelope Glycoprotein AntigensOligomannose GlycansOligomannose GlycosylationVaccine Efficacy TrialsVaccine Immunogen Design
To date, the RV144 HIV vaccine trial has been the only study to show that immunization can confer protection from HIV infection. While encouraging, the modest 31.2% (P = 0.04) efficacy achieved in this study left significant room for improvement, and created an incentive to optimize the AIDSVAX B/E vaccine immunogens to increase the level of vaccine efficacy. Since the completion of the RV144 trial, our understanding of the antigenic structure of the HIV envelope protein, gp120, and of the specificity of broadly neutralizing monoclonal antibodies (bN-mAbs) that bind to it, has significantly improved. In particular, we have learned that multiple families of bN-mAbs require specific oligomannose glycans for binding. Both of the monomeric gp120 immunogens (MN- and A244-rgp120) in the AIDSVAX B/E vaccine used in the RV144 trial were enriched for glycans containing high levels of sialic acid, and lacked critical N-linked glycosylation sites required for binding by several families of bN-mAbs. The absence of these epitopes may have contributed to the low level of efficacy achieved in this study. In this report, we describe our efforts to improve the antigenic structure of the rgp120 immunogens used in the vaccine by optimizing glycan-dependent epitopes recognized by multiple bN-mAbs. Our results demonstrated that by shifting the location of one PNGS in A244-rgp120, and by adding two PNGS to MN-rgp120, in conjunction with the production of both proteins in a cell line that favors the incorporation of oligomannose glycans, we could significantly improve the binding by three major families of bN-mAbs. The immunogens described here represent a second generation of gp120-based vaccine immunogens that exhibit potential for use in RV144 follow-up studies.
62
Antibody neutralization and escape by HIV-1
Xiping Wei, Julie M. Decker, Shuyi Wang et al. · Nature · 2003 · 2.4K citations
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Xueling Wu, Zhi-Yong Yang, Yuxing Li et al. · Science · 2010 · 1.8K citations